Akèy › Myelom Miltip › Virginia
Etid klinik pou Myelom Miltip nan Virginia
20 etid pou Myelom Miltip ap chèche patisipan nan sit nan Virginia.
Vil nan Virginia
Tèks ofisyèl etid la (Anglè)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Gainesville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07391657A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Virginia Commonwealth University - Massey Cancer Center, Richmond
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06500884A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Charlottesville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07073547A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Alexander T. Augusta Military Medical Center, Fort Belvoir
- Virginia Oncology Associates Brock Cancer Center, Norfolk
- Richmond VA Medical Center, Richmond
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05552222A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Virginia Cancer Specialists - Fairfax /ID# 278716, Fairfax
- Blue Ridge Cancer Care - Roanoke /ID# 278722, Roanoke
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Inova Schar Cancer Institute, Fairfax
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- VCU Massey Comprehensive Cancer Center, Richmond
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06465316Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Virginia Oncology Associates, Norfolk
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06297226AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT06106945AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Charlottesville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Fairfax
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT07764978A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Virginia Cancer Specialists - Fairfax /ID# 268559, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT05650632Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Sovah Health Martinsville, Martinsville
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- ak 2 plis
Ap rekriteFaz 3
Tout laj · Tout sèks · Mizajou Jun 10, 2026 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Virginia Oncology Associates, Norfolk
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT05243797Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- Virginia Oncology Associates, Norfolk
Ap rekriteFaz 2
Laj 19 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT06974786A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Fairfax
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Apr 22, 2026 · NCT06679101Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Virginia Cancer Specialists, Fairfax
- Blue Ridge Cancer Center, Roanoke
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 22, 2026 · NCT05972135A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- University of Virginia, Charlottesville
- Virginia Cancer Specialists, Fairfax
- Virginia Oncology Associates, Norfolk
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Mar 24, 2026 · NCT04988555CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- Virginia Commonwealth University, Richmond
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2025 · NCT05722418IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- NEXT Oncology Virginia, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 3, 2025 · NCT06119685Sous ClinicalTrials.gov, done yo ranmase Oct 4, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.